Clinical trial
A Prospective, Multicenter, Randomized Controlled Trial of Fosaprepitant Combined With Tropisetron and Multi-Day Olanzapine Versus Fosaprepitant Combined With Tropisetron and Dexamethasone for the Prevention of Delayed Nausea and Vomiting Induced by High-Dose Chemotherapy in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
NCT07413809 is registered in ClinicalTrials.gov with The Affiliated People's Hospital of Ningbo University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Randomized Controlled Trial of Fosaprepitant Combined With Tropisetron and Multi-Day Olanzapine Versus Fosaprepitant Combined With Tropisetron and Dexamethasone for the Prevention of Delayed Nausea and Vomiting Induced by High-Dose Chemotherapy in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
- Lead sponsor
- The Affiliated People's Hospital of Ningbo University
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 31, 2025
- Completion date
- September 30, 2027
- Enrollment
- 92 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.